By Connor Hart
Arcutis Biotherapeutics promoted Latha Vairavan to chief financial officer, effective immediately, prior to the filing of the company's upcoming first-quarter financial report.
Vairavan most recently was the company's vice president of finance and corporate controller, overseeing daily accounting operations and ensuring compliance with financial, accounting and income tax regulations, the company said Thursday.
She joined the company in March 2020, having previously held roles of increasing responsibility at biopharmaceutical company Amgen.
As CFO of Arcutis, Vairavan's annual base salary will increase to $450,000, according to a filing with the Securities and Exchange Commission. She will additionally be eligible for an annual bonus up to 67.5% of her annual salary, as well as stock options and other benefits.
Vairavan will succeed David Topper, who plans to retire. Topper will provide transition support through his departure from the company, scheduled for May 15.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 10, 2025 17:41 ET (21:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。